Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2015, 24(4):238-242

Hyperuricaemia and clinical relation: heart, kidney and blood vessels

Lietava J
II. interná klinika Lekárská fakulta Univerzita Komenského a Univerzitnej nemocnice Bratislava, Slovenská republika

Uric acid (UA) in its physiological range represents the most important antioxidative mechanism in humans. Hyperuriacemia (HUA) is a severe pro-oxidative factor which is either associated with or causally related to several cardiac or renal diseases. HUA probably causally contributes to development of hypertension in younger patients or in early stages of hypertension, in which decrease of UA may exhibit an inconsistent hypotensive effect. In stroke patients UA level also has significant prognostic value. UA correlates with diagnostics and severity as well as prognosis of ischemic heart disease. In patients with chronic renal diseases the HUA ≥ 500 mmol/l increases 4-9-fold a risk of renal failure or development of end-stage renal diseases (ESRD). Decrease of UA level decreases the risk or at least delays the progression into terminal stage of ESRD. Tab. 4, Ref. 34, Online full text (Free, PDF) www. cardiology.sk

Keywords: uric acid; oxidative stress; atherosclerosis; cardiac and renal diseases

Published: April 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lietava J. Hyperuricaemia and clinical relation: heart, kidney and blood vessels. Cardiology Letters. 2015;24(4):238-242.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Waring WS, Webb DJ, Maxwell SR. Uric acid as a risk factor for cardiovascular disease. QJM. 2000;93(11):707-713. Go to original source...
    2. Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp MF, Simpson A, Gulliver-Sloan F, Maxwell SR, Webb DJ. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude. 2007;131(5):1473-1478.
    3. Sahebjani H. Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 1998;113:1604-1608. Go to original source...
    4. Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Subacius HP, Chioncel O, Maggioni AP, Swedberg K, Zannad F, Konstam MA, Senni M, Givertz MM, Butler J, Gheorghiade M; EVEREST trial investigators. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol 2014;114(11):1713-1721. Go to original source...
    5. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008;392(1-2):1-7. Go to original source...
    6. Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, Jones AF, Barnett AH. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 1997;2:484-907. Go to original source...
    7. Hulín I. Patofyziológia pre lekárov a študentov medicíny. (7 vyd.) Bratislava: SAP; 2009:1288.
    8. Qasi Y, Batuman V. 2014. http://emedicine.medscape.com/article/241767-overview#a5
    9. Kuo CF, Yu KH, See LC, Chou IJ, Tseng WY, Chang HC, Shen YM, Luo SF. Elevated risk of mortality among gout patients. Joint Bone Spine. 2011;78(6):577-580. Go to original source...
    10. Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124(2):155-163. Go to original source...
    11. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009;21(2):132-137. Go to original source...
    12. Choi YJ, Yoon Y, Lee KY, Hien TT, Kang KW, Kim KC, Lee J, Lee MY, Lee SM, Kang DH, Lee BH. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197-3204. Go to original source...
    13. Jalal DI, Jablonski KL, McFann K, Chonchol MB, Seals DR. Vascular endothelial function is not related to serum uric acid in healthy adults. Am J Hypertens. 2012;(4):407-413. Go to original source...
    14. de Coutinho AT, Turner ST, Kullo IJ. Serum uric acid is associated with microvascular function in hypertensive individuals. J Hum Hypertens. 2007;21(8):610-615. Go to original source...
    15. Krishnan E. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009-2010. J Am Heart Assoc. 2014;3(2):e000157. Go to original source...
    16. Tsioufis C, Kyvelou S, Dimitriadis K, Syrseloudis D, Sideris S, Skiadas I, Katsi V, Stefanadi E, Lalos S, Mihas C, Poulakis M, Stefanadis C. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Hum Hypertens. 2011;25(9):554-549. Go to original source...
    17. Erdogan D, Icli A, Aksoy F, Akcay S, Ozaydin M, Ersoy I, Varol E, Dogan A. Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure. Chronobiol Int. 2013;(8):973-980. Go to original source...
    18. Tsai WC1, Huang YY, Lin CC, Li WT, Lee CH, Chen JY, Chen JH. Uric acid is an independent predictor of arterial stiffness in hypertensive patients. Heart Vessels. 2009;24(5):371-375.
    19. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73(12):1059-1064. Go to original source...
    20. de Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy PF 2nd, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20(1):83-89. Go to original source...
    21. Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders-facts and controversies. Biochem Med (Zagreb). 2012;22(1):63-75. Go to original source...
    22. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9(1):13-23. Go to original source...
    23. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, Prins MWJ, and Roest M. Circulating Biomarkers for Predicting Cardiovascular Disease Risk; a Systematic Review and Comprehensive Overview of Meta-Analyses. PLoS One. 2013;8(4): e62080. Go to original source...
    24. Jelić-Ivanović Z, Memon L, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Spasić S. Independent association of high serum uric acid concentration with angiographically defined coronary artery disease. Tohoku J Exp Med. 2007;211(4):369377. Go to original source...
    25. Sinan Deveci O, Kabakci G, Okutucu S, Tulumen E, Aksoy H, Baris Kaya E, Evranos B, Aytemir K, Tokgozoglu L, Oto A. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64(7):900-907. Go to original source...
    26. Duran M, Kalay N, Akpek M, Orscelik O, Elcik D, Ocak A, Inanc MT, Kasapkara HA, Oguzhan A, Eryol NK, Ergin A, Kaya MG. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology. 2012;63(6):448-452. Go to original source...
    27. Gur M, Yilmaz R, Demirbag R, Aksoy N. Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease. Angiology. 2008;59(2):166-171. Go to original source...
    28. Rothenbacher D, Kleiner A, Koenig W, Primatesta P, Breitling LP, Brenner H. Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease. PLoS One. 2012;7(9):e45907. Go to original source...
    29. Meisinger C, Koenig W, Baumert J, Döring A. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol. 2008;28(6):1186-1192. Go to original source...
    30. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000;10:403-409. Go to original source...
    31. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 4:642-650. Go to original source...
    32. Sin Y, Leung K, Tong M, Kwan T. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-59. Go to original source...
    33. Šašinka M, Furková K. Aktuálne problémy hyperurikémie Lek Obz 2011;60(1):18-26.
    34. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.Am J Kidney Dis. 2015;65(4):543-549. Go to original source...

    Return to the content